The increased expression of NKG2A and IL-2Rβγ in tumor-infiltrated immune effector cells suggested that the majority of intravenously administrated NKG2A-targeted IL-2Rβγ agonist would be delivered into tumor grafts of mice. This evidence concerns the gene KLRC1 and neoplasm.